The MAP3K14 (Mitogen-Activated Protein Kinase Kinase Kinase 14) antibody is a crucial tool for studying the NF-κB signaling pathway. MAP3K14. also known as NIK (NF-κB-inducing kinase), is a serine/threonine kinase that activates the non-canonical NF-κB pathway by phosphorylating IKKα. This pathway regulates immune responses, B-cell survival, lymphoid organogenesis, and osteoclast differentiation. Dysregulation of MAP3K14 is linked to cancers, autoimmune disorders, and inflammatory diseases.
Antibodies targeting MAP3K14 are widely used in Western blotting, immunohistochemistry, immunoprecipitation, and flow cytometry to detect protein expression, localization, and activation status. They help identify MAP3K14's role in cellular processes and disease mechanisms. High-quality MAP3K14 antibodies exhibit specificity for distinct isoforms or phosphorylation states, validated via knockout controls or siRNA knockdown.
Research applications include investigating MAP3K14's interaction with TRAF proteins, its degradation via ubiquitination, and its crosstalk with other signaling pathways. Commercial antibodies are typically raised in rabbits or mice, with monoclonal and polyclonal variants available. Proper validation ensures minimal cross-reactivity with related kinases (e.g., MAP3K1/2). As therapeutic targeting of NF-κB pathways advances, MAP3K14 antibodies remain vital for preclinical studies and biomarker discovery.